University Hospital, Basel, Switzerland: Multiple Sclerosis trials

The registry lists 17 Multiple Sclerosis studies with University Hospital, Basel, Switzerland as lead sponsor. 6 are open to participants now and 0 have results posted.

No phase 17(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)RecruitingNCT06526364
• REtinal Markers In Neuroinflammatory Diseases ("REMIND")RecruitingNCT06369766
• Imaging the Interplay Between Axonal Damage and Repair in Multiple SclerosisRecruitingNCT05177523
• Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI SequencesRecruitingNCT04819737Not applicable
• Swiss Multiple Sclerosis Cohort-StudyRecruitingNCT02433028
• Quantified Balance Measures During Stance and Gait: Multiple Sclerosis Patients. A Longitudinal Clinical StudyRecruitingNCT02142946
• MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within the SMSCActive, not recruitingNCT06095271Not applicable
• Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®CompletedNCT05575843Not applicable
• A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.CompletedNCT04760990
• Combined Sensitivity and Specificity of Cortical Lesions and Central Vein Sign for MS Diagnosis and Differential DiagnosisCompletedNCT04369898
• Prospective Stratification of Infectious Risks in Multiple SclerosisCompletedNCT04036097
• Spinal Cord Analysis in Multiple SclerosisCompletedNCT03841903
• Feasibility and Reliability of Multimodal Evoked PotentialsCompletedNCT03686826
• Motor Evoked Potentials With Modified Facilitation TechniqueCompletedNCT03646929Not applicable
• Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple SclerosisCompletedNCT03632473
• Disease Control in RRMS Transferring Treatment From Natalizumab to FingolimodCompletedNCT02277964
• Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)CompletedNCT01765361